Neose gets approval to begin Western European clinical trials of anemia drug

By Ted A. Knutson

Washington, Jan. 3 - Neose Technologies Inc. announced Tuesday that it has been notified by the regulatory authority in a Western European jurisdiction that it can begin human clinical trials for NE-180, the company's long-acting, GlycoPEGylated erythropoietin for the treatment of anemia.

The company expects to start a phase 1, single ascending-dose trial in healthy volunteers next month and conclude the trial in mid-2006.

Neose is a Horsham, Pa., biopharmaceutical company using its proprietary enzymatic technologies to develop improved drugs, focusing primarily on therapeutic proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.